Roche says Tecentriq combination cuts lung cancer risk
November 20, 2017 at 01:16 AM EST
ZURICH, Nov 20 (Reuters) - A late-stage trial of Roche's immuno-oncology medicine Tecentriq with other cancer drugs as an initial therapy for lung cancer met its goal of significantly reducing the risk of disease worsening or death, the Swiss drugmaker said on Monday.